Study shows precision and reproducibility of PAM50-based Prosigna breast cancer Assay in multiple clinical tests

17-03-2014 Business Wire HealthComments (0)


NanoString Technologies, (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in the journal BMC Cancer demonstrates the analytical validity of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay. Based on highly concordant results across multiple clinical laboratory sites, technicians, and manufacturing lots of Prosigna reagents, the authors

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top